We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Modifies Monitoring for Clozapine to Address Neutropenia Risk
FDA Modifies Monitoring for Clozapine to Address Neutropenia Risk
The FDA has clarified prescribing information for antipsychotic drug clozapine, explaining how to monitor and manage treatment of patients with neutropenia.